Results 131 to 140 of about 12,747 (228)

The Therapeutic Potential of H2S‐Releasing Platforms in Cardiovascular Applications

open access: yesJournal of Biomedical Materials Research Part B: Applied Biomaterials, Volume 114, Issue 8, August 2026.
The Therapeutic Potential of H2S‐Releasing Platforms. ABSTRACT Once known as a toxic gas, hydrogen sulfide (H2S) is now making its way into many therapeutic applications. Similar to its other fellow endogenous gasotransmitters, nitric oxide and carbon monoxide, H2S is a small gas with a short half‐life, making it extremely capable of penetrating ...
Tia N. Shorter, Elizabeth J. Brisbois
wiley   +1 more source

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong   +6 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

open access: yesPhytotherapy Research, Volume 40, Issue 8, Page 4759-4791, August 2026.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee   +9 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano   +4 more
wiley   +1 more source

Willing to Donate? A Quantitative and Thematic Analysis of Attitudes to Deceased Organ Donation in Different Circumstances

open access: yesHealth Expectations, Volume 29, Issue 4, August 2026.
ABSTRACT Introduction The UK public's willingness to donate, knowledge of, and concerns about different organ donation scenarios are not known. Methods A validated questionnaire was developed based on a literature review of the ethical issues associated with uncontrolled Donation after Circulatory Death (uDCD).
Weiyi Tan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy